- Company
- CKD Bio & Cutia Therapeutics signed a supply contract
- by Chon, Seung-Hyun Jan 21, 2022 05:55am
- CKD Bio is targeting overseas markets for botulinum toxin drugs under development. CKD Bio announced on the 19th that it has signed a supply contract with Cutia Therapeutics for Tyemvers, a botulinum toxin. The size of the contract is 8.3 billion won, which supplies the product to China, Hong Kong, Macau, and Taiwan for 15 years after licensing
- Company
- 60 billion won worth of neutropenia market fluctuates
- by Kim, Jin-Gu Jan 20, 2022 05:55am
- The market for neutropenia treatments worth 60 billion won a year is expected to fluctuate significantly. The copyright of the No. 1 and No. 2 items in the second-generation neutropenia treatment market has shifted in succession, and new drugs have joined the competition in six years, signaling a upheaval. ◆Boryung and Jeil will cha
- Company
- Second new migraine drug ‘Ajovy’ aims at reimbursement
- by Eo, Yun-Ho Jan 20, 2022 05:55am
- ‘Ajovy’ is also following the steps of ‘Emgality’ and seeks health insurance benefits in Korea. According to industry sources, Teva-Handok Pharma applied for the reimbursement of its calcitonin gene-related peptide (CGRP) targeting migraine drug Ajovy (fremanezumab). The company quickly applied for reimbursement since launching the dr
- Policy
- Dong-A ST enters Phase III trial for its new OAB treatment
- by Lee, Tak-Sun Jan 20, 2022 05:55am
- News of new drugs being developed by local companies are coming in one after another from early on this year. Dong-A ST, which had developed three new drugs including the erectile dysfunction treatment ‘Zydena (udenafil),’ antibiotic ‘Sivestro (tedizolid phosphate),’ and antidiabetic ‘Suganon (evogliptin),’ is also receiving attentio
- Policy
- SK Bioscience has completed recruiting phase 3 participants
- by Kim, Jung-Ju Jan 20, 2022 05:55am
- The COVID-19 vaccine GBP510, which is being developed by Korean companies, is undergoing phase 3 global clinical trials. The recruitment of 4,000 people from six countries has been completed. Today (18th), the government held the 26th meeting of the pan-government TF to support clinical trials of COVID-19 vaccines and treatments to discuss
- Policy
- Additional Paxlovid for 10,000 people will be introduced
- by Kang, Shin-Kook Jan 20, 2022 05:54am
- Prime Minister Kim Bu-gyeom announced that he would introduce an additional 10,000 servings at the end of this month as patients' condition improved after taking the COVID-19 treatment. Prime Minister Kim posted a message on his SNS on the 17th and said, "The prescription and administration of COVID-19 treatment began last week." He said,
- Company
- PCSK9i Praluent can be prescribed after 5 years of approval
- by Eo, Yun-Ho Jan 19, 2022 06:07am
- Praluent can be prescribed at general hospitals. As a result, practical competition for PCSK9 inhibitors began five years after domestic approval. According to related industries, Sanofi-Aventis Korea's Praluent (Alirocumab) passed the Drug Committee of medical institutions such as Seoul National University Bundang Hospital, Gangnam Sever
- Company
- 3 Korean companies accelerate Stelara biosimilar development
- by Ji Yong Jun Jan 19, 2022 06:06am
- Korean companies are rushing to get a share of Stelara’s autoimmune disease treatment market that brings in &8361;9 trillion in annual sales. Samsung Bioepis, which had been late in starting the development of Stelara biosimilars than its competitors like Dong-A ST and Celltrion, completed patient recruitment for its Phase III trial and pu
- Policy
- Bill for Rotarix·RotaTeq to be covered by NIP
- by Lee, Jeong-Hwan Jan 19, 2022 06:06am
- A bill to promote the health of infants and young children while reducing consumer burden by including rotavirus vaccines in the National Immunization Program (NIP) is being promoted. If passed, the bill will turn GSK’s Rotarix and MSD’s RotaTeq that are already being used in Korea into free national vaccinations. Since the WHO recomme
- Company
- Exporting medicines to North America ↑ 2.6 times in 2 years
- by Kim, Jin-Gu Jan 19, 2022 06:06am
- Exports of domestic drugs hit an all-time high last year, especially exports to the North American market surged, the report showed. Exports to the U.S. and Canada have increased 2.6 times in two years. Germany is still the largest exporter, but it is estimated to have decreased slightly compared to last year. In addition, exports of medic
